Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Miaojun Han"'
Autor:
Perla Pucci, Liam C. Lee, Miaojun Han, Jamie D. Matthews, Leila Jahangiri, Michaela Schlederer, Eleanor Manners, Annabel Sorby-Adams, Joshua Kaggie, Ricky M. Trigg, Christopher Steel, Lucy Hare, Emily R. James, Nina Prokoph, Stephen P. Ducray, Olaf Merkel, Firkret Rifatbegovic, Ji Luo, Sabine Taschner-Mandl, Lukas Kenner, G. A. Amos Burke, Suzanne D. Turner
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-19 (2024)
Abstract Targeting Anaplastic lymphoma kinase (ALK) is a promising therapeutic strategy for aberrant ALK-expressing malignancies including neuroblastoma, but resistance to ALK tyrosine kinase inhibitors (ALK TKI) is a distinct possibility necessitati
Externí odkaz:
https://doaj.org/article/12cef060f54047bf95b2dad4e211f0d7
Autor:
Ricky M. Trigg, Liam C. Lee, Nina Prokoph, Leila Jahangiri, C. Patrick Reynolds, G. A. Amos Burke, Nicola A. Probst, Miaojun Han, Jamie D. Matthews, Hong Kai Lim, Eleanor Manners, Sonia Martinez, Joaquin Pastor, Carmen Blanco-Aparicio, Olaf Merkel, Ines Garces de los Fayos Alonso, Petra Kodajova, Simone Tangermann, Sandra Högler, Ji Luo, Lukas Kenner, Suzanne D. Turner
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-13 (2019)
Anaplastic lymphoma kinase (ALK) inhibitors are currently being considered in neuroblastoma (NB), but its acquired resistance is reported in non-small cell lung cancers. Here, the authors have found PIM1 overexpression decreases sensitivity to ALK in
Externí odkaz:
https://doaj.org/article/f2be0a65707b41b5b2ef0367cf79b3cb
Publikováno v:
PLoS ONE, Vol 7, Iss 9, p e45402 (2012)
Malignant gliomas represent one group of tumors that poorly respond to ionizing radiation (IR) alone or combined with chemotherapeutic agents because of the intrinsic or acquired resistance. In this study, TIP-1 was identified as one novel protein th
Externí odkaz:
https://doaj.org/article/4ca4bc111e1946dfaae90120301231de
Publikováno v:
PLoS ONE, Vol 5, Iss 8, p e12051 (2010)
Tumor response to treatment has been generally assessed with anatomic and functional imaging. Recent development of in vivo molecular and cellular imaging showed promise in time-efficient assessment of the therapeutic efficacy of a prescribed regimen
Externí odkaz:
https://doaj.org/article/0621c31b13b14635b08f32a46cc1290b
Autor:
Perla Pucci, Liam Lee, Miaojun Han, Jamie Matthews, Leila Jahangiri, Eleanor Manners, Annabel Sorby-Adams, Michaela Schlederer, Joshua Kaggie, Ricky Trigg, Nina Prokoph, Stephen Ducray, Olaf Merkel, Firkret Rifatbegovic, Ji Luo, Sabine Taschner-Mandl, Lukas Kenner, Gladstone Burke, Suzanne Turner
Targeting Anaplastic lymphoma kinase (ALK) is a promising therapeutic strategy for aberrant ALK-expressing malignancies including neuroblastoma (NB), but resistance to ALK inhibitors (ALK TKI) is a distinct possibility necessitating drug combination
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::03fb12e52472832b93539d060db62543
https://doi.org/10.21203/rs.3.rs-2167328/v1
https://doi.org/10.21203/rs.3.rs-2167328/v1
Autor:
Petra Kodajova, Sonia Sánchez Martínez, Nicola A. Probst, Liam C. Lee, Ines Garces de los Fayos Alonso, Miaojun Han, Sandra Högler, Joaquín Pastor, G. A. Amos Burke, C. Patrick Reynolds, Hong Kai Lim, Eleanor Manners, Carmen Blanco-Aparicio, Leila Jahangiri, Jamie D. Matthews, Ji Luo, Suzanne D. Turner, Nina Prokoph, Simone Tangermann, Lukas Kenner, Olaf Merkel, Ricky M Trigg
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-13 (2019)
Nature Communications
Repisalud
Instituto de Salud Carlos III (ISCIII)
Nature Communications
Repisalud
Instituto de Salud Carlos III (ISCIII)
Resistance to anaplastic lymphoma kinase (ALK)-targeted therapy in ALK-positive non-small cell lung cancer has been reported, with the majority of acquired resistance mechanisms relying on bypass signaling. To proactively identify resistance mechanis
Autor:
Perla Pucci, Liam Lee, Suzanne Turner, Leila Jahangiri, Jamie Matthews, Amos Burke, Patrick Reynolds, Lukas Kenner, Olaf Merkel, Fikret Rifatbegovic, Ji Luo, Peter Ambros, MiaoJun Han
Publikováno v:
Cancer Research. 82:5344-5344
Anaplastic lymphoma kinase (ALK)-targeted therapy is a promising strategy for the treatment of ALK-positive neuroblastoma (NB). Several ALK tyrosine kinase inhibitors (ALK TKIs) have been approved for the treatment of Non-Small Cell Lung Carcinoma (N
Autor:
Jay A. Berzofsky, Qiong Fu, Shurjo K. Sen, Mathuros Ruchirawat, Qianfei Zhang, Firouzeh Korangy, Valerie Fako, Thomas Ritz, Bernd Heinrich, Giorgio Trinchieri, Miaojun Han, Chi Ma, John A. McCulloch, Vishal Thovarai, Milan Sandhu, Xin Wei Wang, Thomas Longerich, Masaki Terabe, Wuxing Yuan, Casey M. Theriot, Soumen Roy, David Agdashian, Tim F. Greten
Publikováno v:
Science. 360
INTRODUCTION Primary liver tumors and liver metastasis currently represent the leading cause of cancer-related deaths. The liver intimately cross-talks with the gut and performs many essential functions related to digestion, metabolism of nutrients,
Publikováno v:
Cancer Immunology, Immunotherapy. 64:931-940
Myeloid-derived suppressor cells are key components of tumor-induced immune suppression. They are composed of a heterogeneous population of immature myeloid cells that abrogates innate and adaptive immune responses. Myeloid-derived suppressor cells a
Autor:
Firouzeh Korangy, Tim F. Greten, Josef Wissing, Michael P. Manns, Elizabeth M. Jaffee, Miaojun Han, Lothar Jaensch, Chi Ma, Tamar Kapanadze, Todd D. Armstrong, Jaba Gamrekelashvili, Ayla O. White, Deborah Citrin
Publikováno v:
Journal of Clinical Investigation. 123:4755-4768
Cross-priming of CD8 + T cells and generation of effector immune responses is pivotal for tumor immunity as well as for successful anticancer vaccination and therapy. Dead and dying cells produce signals that can influence Ag processing and presentat